Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2019 Oct 8;34(3):938–941. doi: 10.1038/s41375-019-0587-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — DNMTi treatment increases CD38 cell surface expression. a Bar graph of CD38 expression and cell survival upon treatment with different drugs in the indicated cell lines. Height of the bars indicates the fold change in CD38 MFI (left y-axis) and bold black line shows % cell viability (right y-axis). Both are normalized to DMSO treatment. Colors indicate the drug and concentration used. Data are presented as mean ± SD from 2 to 3 independent experiments with technical triplicate in each experiment. Asterisk indicates a significant difference from DMSO treatment (p ≤ 0.05 using a paired student’s t-test). For AZA treatment results are shown for 3d + 4 treatment. b Bar graph comparing azacytidine and decitabine treatments. As before, height of the bars indicates the fold change in CD38 MFI (left y-axis) and bold black line shows % cell viability (right y-axis). Cell viability is ~95% at 10 uM decitabine compared with ~40% for 1 uM azacytidine. Asterisk indicates a significant difference from DMSO treatment (p ≤ 0.05 using a paired student’s t-test). c CD38 expression on primary MM cells upon decitabine treatment. Gray lines separate different patient samples (IDs on x-axis). The percentage of CD138+ cells in each sample are given in brackets underneath the IDs. Data are presented as mean ± SD from three replicate wells